Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating [Seeking Alpha]
Insight Molecular Diagnostics Inc. (IMDX)
Company Research
Source: Seeking Alpha
IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab competitors. Key risks include clinical validation, regulatory approval uncertainty, software readiness, potential FDA delays, and a limited cash runway likely requiring further capital raises. Applying a Hold rating as IMDX advances toward FDA filing by end-2025 and eyes expansion into heart and lung transplant assays in 2026 and 2027. frentusha/iStock via Getty Images I'm beginning coverage of Insight Molecular Diagnostics Inc. IMDX ) with a Hold rating. The reason why I believe it is important to place such a rating on this stock is because it is gearing More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week f
Show less
Read more
Impact Snapshot
Event Time:
IMDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDX alerts
High impacting Insight Molecular Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
IMDX
News
- Oncocyte (NASDAQ:IMDX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oncocyte (NASDAQ:IMDX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d-)" rating on the stock.MarketBeat
- Oncocyte (NASDAQ:IMDX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> tMarketBeat
- This Biotech Stock Is Up 158% in a Year. What's Driving It Higher? [Yahoo! Finance]Yahoo! Finance
- Insight Molecular Diagnostics Inc (IMDX) Q3 2025 Earnings Call Highlights: Pioneering Advances ... [Yahoo! Finance]Yahoo! Finance
IMDX
Sec Filings
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- 11/4/25 - Form 4
- IMDX's page on the SEC website